• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·NH.NS
Share

Narayana Hrudayalaya Limited Stocks

₹ 1961.5Last Updated 24.07.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

₹ 4.28B

₹ 1961.5
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Narayana Hrudayalaya Limited, established in 2000 and headquartered in Bengaluru, India, operates as a prominent provider of medical and healthcare services. The company oversees and manages a diverse range of healthcare facilities, encompassing hospitals, clinics, health centers, and nursing homes. It delivers specialized care across a comprehensive spectrum of medical disciplines, including cardiology, cardiac surgery, nephrology, urology, neurology, neuro-surgery, endocrinology, orthopedics, internal medicine, obstetrics, gynecology, pediatrics, neonatology, gastroenterology, and oncology. As of June 30, 2022, Narayana Hrudayalaya maintained an extensive network that included 19 owned or operated hospitals, 2 managed hospitals, 4 heart centers, and 18 clinics and information centers throughout India, complemented by an international presence with one hospital in the Cayman Islands. Additionally, the company extends its expertise through healthcare consultancy services, which involve the licensing of its ERP solutions.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'expensive'

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
4/7

The average target price of NH.NS is 2175 and suggests 10.9% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.07.2026 21:33

Revolut Valued at $115 Billion and a Record-Breaking Deal in Asia: Key Takeaways on IPOs as of July 26

26.07.2026 15:01

AI Tools to Combat Cognitive Biases: How Investors Can Use Them

25.07.2026 16:01

Small caps last week: New Nasdaq rules, AI hurting Tripadvisor, Archer's rotorcraft

25.07.2026 13:50

Chevron Discussed with the U.S. How to Protect Its Interests in Kazakhstan from the Effects of the War — WSJ

25.07.2026 13:01

The "Three Seas" Risk Zone, Tesla Hit by Expenses, and "Odyssey" — the Driving Force Behind Movie Theaters

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026